by David Cochran | Feb 20, 2017 | Estoppel, Trial Institution
By Rich Graham and Dave Cochran The Federal Circuit’s decision in Shaw[1] affirmed the PTAB’s policy that a Petitioner was not estopped from requesting inter partes review (“IPR”) based on prior art previously included in a petition for IPR, but for which institution...
by Cary Miller | Feb 17, 2017 | Evidentiary Issues, Trial Institution
By Lin Yu, Ph.D. and Cary Miller, Ph.D. In IPR2016-01566 (Mylan Pharmaceuticals Inc. v. Boehringer Ingelheim International GMBH), the PTAB denied institution of an inter partes review of U.S. Patent No. 9,173,859, in part, because Petitioner –Mylan – failed to provide...
by Joe Sauer | Feb 2, 2017 | Trial Institution
By Joe Sauer The PTAB recently dismissed three IPR Petitions filed against the University of Florida Research Foundation on the basis of Eleventh Amendment sovereign immunity. See, Covidien LP v University of Florida Research Foundation Incorporated, IPR2016-01274;...
by Cary Miller | Jan 6, 2017 | Pharmaceutical, Trial Institution
By Unmesh Shah, Ph.D. and Cary Miller, Ph.D. The PTAB instituted an IPR on claims of Mayne Pharma International Pty Ltd.’s (“Mayne”) U.S. Patent No. 6,881,745 B2 covering formulations of azole antifungals in IPR2016-01186. In response to Merck Sharp & Dohme...
by Matthew Johnson | Jan 4, 2017 | Federal Circuit Appeal, Real Party in Interest, Time Limits, Trial Institution
By Matt Johnson Today the Federal Circuit agreed to rehear en banc the panel decision in Wi-Fi One v. Broadcom Corp. on the issue of whether the PTAB’s findings regarding 35 U.S.C. § 315(b)’s one year bar can be reviewed on appeal. This question tests the...
by Jones Day's PTAB Team | Dec 21, 2016 | Pharmaceutical, Trial Institution
By Jeff Giering, Ph.D. and Cary Miller, Ph.D. On November 30, 2016, the PTAB issued decisions on the institution of inter partes reviews of U.S. Patent No. 6,667,061 (the ’061 patent), which relates to formulations for injectable suspensions having increased...
